X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1022) 1022
Publication (155) 155
Book Review (10) 10
Dissertation (5) 5
Book Chapter (4) 4
Conference Proceeding (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
btk (586) 586
humans (539) 539
index medicus (496) 496
ibrutinib (266) 266
animals (265) 265
x-linked agammaglobulinemia (239) 239
protein-tyrosine kinases - metabolism (225) 225
brutons tyrosine kinase (221) 221
bruton's tyrosine kinase (218) 218
activation (215) 215
protein-tyrosine kinases - genetics (203) 203
mice (192) 192
oncology (190) 190
hematology (188) 188
tyrosine (186) 186
protein-tyrosine kinases - antagonists & inhibitors (185) 185
chronic lymphocytic-leukemia (184) 184
immunology (175) 175
male (171) 171
mutation (158) 158
biochemistry & molecular biology (149) 149
targeting btk (137) 137
hemic and lymphatic diseases (129) 129
female (128) 128
signal transduction (126) 126
agammaglobulinemia - genetics (124) 124
protein kinase inhibitors - pharmacology (115) 115
expression (109) 109
leukemia, lymphocytic, chronic, b-cell - drug therapy (109) 109
phosphorylation (101) 101
leukemia (96) 96
pci-32765 (95) 95
cell biology (94) 94
lymphoma (93) 93
pyrimidines - pharmacology (89) 89
pyrimidines - therapeutic use (89) 89
agammaglobulinaemia tyrosine kinase (88) 88
pyrazoles - therapeutic use (85) 85
article (84) 84
btk inhibitor (83) 83
pharmacology & pharmacy (81) 81
protein kinase inhibitors - therapeutic use (81) 81
lymphomas (80) 80
chronic lymphocytic leukemia (79) 79
cancer (76) 76
chemistry, medicinal (75) 75
receptor (75) 75
xla (74) 74
bruton tyrosine kinase (73) 73
protein-tyrosine kinases - chemistry (73) 73
pyrazoles - pharmacology (72) 72
protein-tyrosine kinase (70) 70
immune system diseases (69) 69
apoptosis (68) 68
b-cell receptor (67) 67
kinases (67) 67
adult (66) 66
agammaglobulinemia (64) 64
analysis (64) 64
gene (64) 64
inhibitor (64) 64
therapy (62) 62
b-lymphocytes - immunology (61) 61
cell line, tumor (61) 61
rituximab (60) 60
antineoplastic agents - therapeutic use (59) 59
cll (58) 58
research (58) 58
b cells (56) 56
btk gene (56) 56
mantle cell lymphoma (56) 56
mutations (56) 56
antineoplastic agents - pharmacology (55) 55
child (55) 55
proteins (55) 55
signal transduction - drug effects (55) 55
aged (54) 54
immunodeficiency (54) 54
care and treatment (53) 53
b-cell (52) 52
phenols (51) 51
protein kinase inhibitors - chemistry (51) 51
genetic aspects (50) 50
middle aged (50) 50
b-lymphocytes - metabolism (49) 49
bruton’s tyrosine kinase (49) 49
abridged index medicus (48) 48
cell line (48) 48
btk inhibitors (47) 47
cells (47) 47
lymphocytes b (47) 47
open-label (47) 47
survival (47) 47
tyrosine kinase (47) 47
child, preschool (46) 46
genetic diseases, x-linked - genetics (46) 46
pyrimidines - adverse effects (46) 46
genetics & heredity (45) 45
leukemia, lymphocytic, chronic, b-cell - pathology (45) 45
x chromosome (45) 45
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1021) 1021
French (4) 4
Japanese (2) 2
Chinese (1) 1
German (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cancer, ISSN 1476-4598, 02/2018, Volume 17, Issue 1, p. 57
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of... 
Chronic lymphocytic leukemia | Tumor microenvironment | B cell receptor signaling | Leukemia | Chemokine receptor | B cell development | Bruton's tyrosine kinase | Lymphoma | Ibrutinib | SIGNALING PATHWAYS | BIOCHEMISTRY & MOLECULAR BIOLOGY | X-LINKED AGAMMAGLOBULINEMIA | FACTOR-KAPPA-B | ATRIAL-FIBRILLATION | BTK INHIBITOR IBRUTINIB | TEC KINASE | ONCOLOGY | THERAPEUTIC TARGET | CHRONIC LYMPHOCYTIC-LEUKEMIA | TUMOR-ASSOCIATED MACROPHAGES | BETA-GAMMA-SUBUNITS | Leukemia, B-Cell - metabolism | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Tumor Microenvironment | Leukemia, B-Cell - etiology | Receptors, Antigen, B-Cell - metabolism | Molecular Targeted Therapy | Biomarkers, Tumor | Cell Differentiation - genetics | Agammaglobulinaemia Tyrosine Kinase - metabolism | Cell Transformation, Neoplastic - genetics | Leukemia, B-Cell - drug therapy | Agammaglobulinaemia Tyrosine Kinase - chemistry | B-Lymphocytes - pathology | Gene Expression Regulation, Neoplastic - drug effects | Lymphoma, B-Cell - etiology | Bone Marrow | B-Lymphocytes - metabolism | Lymphoma, B-Cell - drug therapy | Lymphoma, B-Cell - metabolism | Lymphopoiesis - ethics | Leukemia, B-Cell - pathology | Treatment Outcome | Cell Transformation, Neoplastic - metabolism | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Lymphoma, B-Cell - pathology | Agammaglobulinaemia Tyrosine Kinase - genetics | Protein Kinase Inhibitors - pharmacology | Care and treatment | Usage | Lymphomas | Research | Chemokines | Cancer
Journal Article
by Lv, JH and Wu, JD and He, F and Qu, Y and Zhang, QQ and Yu, CG
CURRENT MEDICINAL CHEMISTRY, ISSN 0929-8673, 2018, Volume 25, Issue 42, pp. 5847 - 5859
Journal Article
Leukemia, ISSN 0887-6924, 10/2017, Volume 31, Issue 10, pp. 2075 - 2084
Although the BTK inhibitor ibrutinib has transformed the management of patients with chronic lymphocytic leukemia (CLL), it does not induce substantial... 
MULTICENTER | CLL CELLS | THERAPY | ONCOLOGY | MCL-1 | IBRUTINIB | RESISTANCE | BTK | LYMPHOMA | OPEN-LABEL | HEMATOLOGY | ABT-199 | Peptide Fragments | Pyrazoles - therapeutic use | Proto-Oncogene Proteins c-bcl-2 - physiology | Apoptosis - drug effects | Humans | Neoplasm Proteins - physiology | Pyrazines - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - agonists | Neoplasm Proteins - antagonists & inhibitors | Pyrazines - therapeutic use | Molecular Targeted Therapy | Benzamides - administration & dosage | Benzamides - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Sulfonamides - agonists | Benzamides - pharmacology | Proto-Oncogene Proteins | Pyrazoles - pharmacology | Pyrimidines - administration & dosage | Bcl-2-Like Protein 11 - genetics | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Clinical Trials as Topic | Mitochondria - drug effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Bcl-2-Like Protein 11 - biosynthesis | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Protein Kinase Inhibitors - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Pyrazines - pharmacology | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | Drug Screening Assays, Antitumor | Protein-Tyrosine Kinases - antagonists & inhibitors | Enzymes | Chronic lymphocytic leukemia | Care and treatment | Development and progression | Genetic aspects | Regulation | Drug resistance | Health aspects | Killing | Tyrosine | Drugs | Medical research | Chronic lymphatic leukemia | Bcl-2 protein | Leukemia | Clinical trials | Priming | Lymphatic leukemia | Patients | Bruton's tyrosine kinase | Mitochondria | Inhibitors | Cell death | Sensitivity enhancement | Inhibition | Pretreatment | Protein-tyrosine kinase | BIM protein | Apoptosis
Journal Article
Bioorganic and Medicinal Chemistry Letters, ISSN 0960-894X, 03/2015, Volume 25, Issue 6, pp. 1333 - 1337
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 03/2018, Volume 61, Issue 6, pp. 2227 - 2245
Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fc gamma... 
IRREVERSIBLE INHIBITORS | CHEMISTRY, MEDICINAL | BTK INHIBITOR | INFLAMMATORY DISEASES | B-CELL MALIGNANCIES | MURINE LUPUS | DRUG DESIGN | IBRUTINIB | CHRONIC LYMPHOCYTIC-LEUKEMIA | MEDIATED GLOMERULONEPHRITIS | TARGETING BTK
Journal Article
Journal Article
Journal Article
Journal Article
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, ISSN 0027-8424, 05/2019, Volume 116, Issue 19, pp. 9390 - 9399
Bruton's tyrosine kinase (Btk) is critical for B cell proliferation and activation, and the development of Btk inhibitors is a vigorously pursued strategy for... 
BTK FUNCTION | PROTEIN | PHOSPHORYLATION | enhanced sampling | MULTIDISCIPLINARY SCIENCES | dimerization | PH DOMAIN | allosteric activation | Bruton's tyrosine kinase | AUTOINHIBITION | B-CELL | EQUILIBRIUM | DYNAMICS | PIP3 | BINDING | ASSOCIATION | Tyrosine | Molecular dynamics | Phenols | Cell membranes | B cells
Journal Article
Current Hematologic Malignancy Reports, ISSN 1558-8211, 03/2014, Volume 9, Issue 1, pp. 44 - 49
Journal Article